F. Hoffmann-La Roche Ltd
WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis
WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis
Tuberculosis is a disease of poverty, and economic distress with 1.4 million deaths annually
1 and the growing challenge of drug resistance is adding to the global health crisis
WHO guidelines support the expansion of tuberculosis diagnostics in resource-limited countries, enabling patients to receive timely diagnosis leading to proper treatment, which benefits their recovery and slows the transmission of disease
F Hoffmann-La Roche Ltd: WHO guidelines now include Roche s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
F Hoffmann-La Roche Ltd: Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Message :
Required fields ENSPRYNG is the first and only treatment approved for both adults and adolescents in the EU with AQP4-IgG seropositive NMOSD ENSPRYNG can be used as a monotherapy or in combination with immunosuppressive therapy to reduce relapses and prevent permanent disability In Phase III studies, ENSPRYNG significantly reduced the number and severity of relapses in people with AQP4-IgG seropositive NMOSD Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG(R) (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMOSD treatment that is administered subcutaneously every four weeks, allowing home-dosing af